Zephyr Health, a data analytics platform for companies in the life sciences industry, has announced a $15 million funding round co-led by Kleiner Perkins Caufield & Byers and Jafco Ventures.

In addition to the company's funding, Zephyr Health also announced the addition of Brook Byers, general partner at Kleiner Perkins Caufield & Byers (KPCB), and Joe Horowitz, managing general partner at Jafco Ventures, to its Board of Directors.

'A key problem today for life science companies of all sizes is the enormous scale and variety of data they must deal with in largely disconnected environments,' said William King, CEO and founder of Zephyr Health. 'Zephyr's platform leverages NoSQL data bases, machine-based algorithms, and exceptional visualization to put valuable insights directly into the hands of business leaders and decision-makers. We are delighted to have the support of KPCB and Jafco Ventures in pursuing our mission of transforming data in the life sciences industry.'

Zephyr's platform is specially designed to help life sciences companies improve R&D efforts and bring new treatments to the right physicians in the treatment landscape. Through the platform, customers are able to greatly reduce the time and cost it takes to research and bring a therapy to market. Five of the world's largest pharmaceutical and device companies are already working closely with Zephyr Health and seeing impactful results from the platform.

'Having worked with over 100 innovative pharmaceutical, biotechnology, and medical device companies for decades, Zephyr Health offers the most compelling business solutions that I have seen,' said Brook Byers, general partner at KPCB. 'The insights they afford are nothing short of remarkable and can be of great benefit to everyone from the CEO on down throughout the organization. We look forward to leveraging our extensive industry network to help Zephyr accelerate customer adoption and realize its enormous value.'

'One of the many things that attracted us to Zephyr Health is the quality of their value proposition and their rate of customer traction,' said Joe Horowitz, managing general partner at Jafco Ventures. 'Having worked with industry leaders in cloud computing and the big data spaces, Zephyr clearly stands out as a highly focused business poised for tremendous success.'

It can take up to ten years to get a drug to market at a cost of up to $4 billion. By breaking down the silos that divide data, Zephyr helps connect information that otherwise cannot be seen as a whole so that drug and life sciences companies can bring effective therapies to market faster and less expensively than ever before.

'The ability to intuitively derive value from the data through Zephyr's suite of cloud applications has already changed the landscape of decision-making in life sciences,' said William King. 'Now with this financing from two leading venture firms, we are off to the races to establish Zephyr Health as the leader in data management and analytics for this market.'